Literature DB >> 9642592

Phacoemulsification cataract surgery in vitrectomized eyes.

V Díaz Lacalle1, F J Orbegozo Gárate, N Martinez Alday, J A López Garrido, J Aramberri Agesta.   

Abstract

PURPOSE: To determine the problems, safety, and results of phacoemulsification cataract surgery in previously vitrectomized eyes.
SETTING: Department of Ophthalmology of Galdácano Hospital, Galdacano, Spain.
METHODS: In this prospective study, phacoemulsification was performed in 23 eyes that had had vitrectomy between February 1992 and May 1994. Surgical and postsurgical difficulties and complications and visual acuity results were analyzed. Follow-up ranged from 12 to 24 months.
RESULTS: The incidence of surgical problems and complications was higher than usual: 7 eyes presented small pupil size (< 3.0 mm); sudden changes in anterior chamber depth and pupil size during surgery occurred in 6 eyes; unusual mobility and flaccidity of the posterior capsule was observed in 6 cases, which was associated with posterior subcapsular cataract and young age (< 50 years); posterior capsule tear occurred in 2 eyes, 1 of which required anterior vitrectomy. Postoperatively, best visual acuity improved two Snellen lines or more in 17 eyes (73.91%), did not change in 3 (13.04%), and worsened in 3.
CONCLUSION: Phacoemulsification in vitrectomized eyes presented more problems and complications than usual. However, it seems to be safer than manual extracapsular surgery because it minimized the risk of intraoperative eye hypotony or collapse.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9642592     DOI: 10.1016/s0886-3350(98)80135-1

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  13 in total

1.  Presbyopic phacovitrectomy.

Authors:  R Ling; P Simcock; J McCoombes; S Shaw
Journal:  Br J Ophthalmol       Date:  2003-11       Impact factor: 4.638

2.  A system for preoperative stratification of cataract patients according to risk of intraoperative complications: a prospective analysis of 1441 cases.

Authors:  M Muhtaseb; A Kalhoro; A Ionides
Journal:  Br J Ophthalmol       Date:  2004-10       Impact factor: 4.638

3.  Pars plana vitrectomy, phacoemulsification and intraocular lens implantation. Comparison of clinical complications in a combined versus two-step surgical approach.

Authors:  Felix Treumer; Arnd Bunse; Martin Rudolf; Johann Roider
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-12-03       Impact factor: 3.117

4.  The role of case mix in the relation of volume and outcome in phacoemulsification.

Authors:  M S Habib; C V Bunce; S G Fraser
Journal:  Br J Ophthalmol       Date:  2005-09       Impact factor: 4.638

5.  Intraoperative complications of cataract surgery in the very old.

Authors:  S J Robbie; M Muhtaseb; K Qureshi; C Bunce; W Xing; A Ionides
Journal:  Br J Ophthalmol       Date:  2006-08-09       Impact factor: 4.638

6.  Comparative evaluation of outcomes of phacoemulsification in vitrectomized eyes: silicone oil versus air/gas group.

Authors:  Jeewan S Titiyal; Esha Agarwal; Dewang Angmo; Namrata Sharma; Atul Kumar
Journal:  Int Ophthalmol       Date:  2016-08-02       Impact factor: 2.031

7.  Femtosecond laser-assisted cataract surgery in vitrectomized eye with posterior chamber phakic intraocular lens.

Authors:  Natalia Anisimova; Boris Malyugin; Lisa B Arbisser; Nikolay Sobolev
Journal:  Digit J Ophthalmol       Date:  2017-06-30

8.  Phacovitrectomy without prone posture for full thickness macular holes.

Authors:  P R Simcock; S Scalia
Journal:  Br J Ophthalmol       Date:  2001-11       Impact factor: 4.638

9.  Vitrectomy as a Risk Factor for Complicated Cataract Surgery.

Authors:  Moss J Fenberg; Kenneth J Hainsworth; Frank G Rieger; Dean P Hainsworth
Journal:  Mo Med       Date:  2016 Jan-Feb

10.  Combined Idiopathic Macular Hole Vitrectomy with Phacoemulsification without Face-Down Positioning.

Authors:  Fumihiko Yagi; Seiji Takagi; Goji Tomita
Journal:  J Ophthalmol       Date:  2012-02-20       Impact factor: 1.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.